2型糖尿病患者的新选择:利格列汀  

New choice for type 2 diabetes mellitus:linagliptin

作　　者：欧阳丽辉[1,2] 彭六保[1] 曾小慧[1,2] 王思颖[1,2] 

机构地区：[1]中南大学湘雅二医院药剂科,湖南长沙410011 [2]中南大学药学院,湖南长沙410013

出　　处：《中国新药与临床杂志》2013年第2期92-97,共6页Chinese Journal of New Drugs and Clinical Remedies

基　　金：国家自然科学基金项目(81173028)

摘　　要：利格列汀是新一代二肽基肽酶4抑制剂,用于结合饮食和体育锻炼的成年2型糖尿病患者的血糖控制。目前推荐剂量为5 mg,每日一次。利格列汀单独用药可改善血糖控制,与二甲双胍、吡格列酮、磺脲类联合应用能提高疗效,且不增加不良反应,一系列临床试验证明其耐受性和安全性好。利格列汀与其他药物相互作用少,主要通过粪便排泄,对于肾功能不全的2型糖尿病患者来说是一个更好的选择。Linagliptin, the newest dipeptidyl peptidase-4 inhibitor, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The recommended dose is 5 mg once a day. Linagliptin monotherapy could improve plasma glucose levels control. And combination therapy of linagliptin with other hypoglycemic agents such as metformin, pioglitazone and sulfonylurea, not only was well tolerated, but also could produce significant and clinically meaningful improvements in glycaemic control. A series of clinical trims provided the safety, tolerance and effectiveness evidence for using linagliptin. Drug interactions betteen linagliptin and others rarely occurred. Linagliptin is mainly eliminated via feces, so it could provide a more valuable treatment option for type 2 diabetes mellitus patients with renal impairment.

关 键 词：利格列汀 糖尿病 2型 二肽基肽酶类 

分 类 号：R977.15[医药卫生—药品]